Total revenues for Jazz Pharmaceuticals’ first quarter were $246.9 million, an increase of 26% over total revenues of $196.2 million for the first quarter of 2013. This increase was driven primarily by net product sales of narcolepsy treatment Xyrem (sodium oxybate) oral solution, Erwinaze/Erwinase (asparaginase Erwinia chrysanthemi), and defibrotide, marketed under the name Defitelio in Europe.

Net product sales for the first quarter of 2014 were as follows:

Xyrem: Xyrem net sales increased by 36% to $160.4 million in the first quarter of 2014 compared to $117.5 million in the first quarter of 2013. During the first quarter of 2014, the average number of active Xyrem patients was approximately 11,400.

Erwinaze/Erwinase: Erwinaze/Erwinase net sales increased by 12% to $46.9 million in the first quarter of 2014 compared to $41.8 million in the first quarter of 2013. In connection with the EUSA Pharma acquisition in 2012, the company agreed to make a contingent payment of $50.0 million in cash if Erwinaze achieved net sales in the United States of $124.5 million or more in 2013. This net sales milestone was achieved in the fourth quarter of 2013, and, as a result, the company made the contingent payment in the first quarter of 2014.

Defitelio/defibrotide: On January 23, 2014, Jazz Pharmaceuticals plc acquired indirect majority control of Gentium S.p.A. Defitelio/defibrotide net sales in the first quarter since the January 23, 2014 closing date of the Gentium acquisition were $12.2 million. Pro forma net sales of Defitelio/defibrotide were $15.1 million in the first quarter of 2014, an increase of 75% compared to pro forma net sales of $8.6 million in the first quarter of 2013. The pro forma information represents net sales of Defitelio/defibrotide as if the Gentium acquisition had closed on January 1, 2013.

Prialt (ziconotide) intrathecal infusion: Net sales of Prialt were $4.3 million in the first quarter of 2014, a decrease of 14% compared to $5.0 million in the first quarter of 2013. The decrease in net sales was due in part to the timing of shipments to the exclusive wholesale distributor and central pharmacy for Prialt.

Psychiatry products: Net sales of the company’s psychiatry products were $9.9 million in the first quarter of 2014 compared to $17.7 million in the first quarter of 2013. The decrease was primarily due to the impact of generic competition.

Other: Net sales of other products for the first quarter of 2014 were $11.3 million compared to $12.7 million in the first quarter of 2013. On a pro forma basis, net sales of other products for the first quarter of 2014 were $11.7 million compared to $14.1 million in the first quarter of 2013. The pro forma information includes net sales of active pharmaceutical ingredient by Gentium as if the Gentium acquisition had closed on January 1, 2013.

In April 2014, the company was informed that the Phase 2b data for JZP-110 has been accepted as a late-breaking abstract for oral presentation at SLEEP 2014, the 28th Annual Meeting of the Associated Professional Sleep Societies, LLC in Minneapolis on June 2, 2014.